NEOG Stock Analysis: Neogen | NASDAQ

Diagnostic Kits, Lab Reagents, Vet Instruments, Genomics

Total Rating 64

Safety 79

Buy Signal 0.75

Medical Devices
Industry Rotation: +8.3

Market Cap: 2.58B
Avg Turnover: 24.1M

Risk 3d forecast

Volatility50.8%

VaR 5^th Pctl8.09%

VaR vs Median-2.84%

Reward TTM

Sharpe Ratio1.42

Rel. Str. IBD92.4

Rel. Str. Peer Group93.8

Character TTM

Beta1.815

Beta Downside2.132

Hurst Exponent0.364

Drawdowns 3y

Max DD81.18%

CAGR/Max DD-0.25

CAGR/Mean DD-0.41

EPS (Earnings per Share)

EPS CAGR: -20.73%
EPS Trend: -96.6%

Last SUE: 1.39
Qual. Beats: 3

Revenue

Rev. CAGR: -2.40%
Rev. Trend: -94.0%

Last SUE: 2.17
Qual. Beats: 4

Warnings

Interest Coverage Ratio Critical

Below Avwap Earnings

Tailwinds

Rs Leader

Idiosyncratic Leader

Seasonality 11.6 years of data

Jan -1.1% 17

Feb -2.5% 41

Mar +0.5% 2

Apr -4.8% 48

May +3.4% 32

Jun +7.8% 19

Jul +1.2% 20

Aug -0.4% 5

Sep -4.5% 28

Oct -4.1% 26

Nov +3.3% 39

Dec +2.2% 16

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: NEOG Neogen

Neogen Corporation is a global developer, manufacturer, and marketer of products and services for food and animal safety, organized into two reporting segments. The Food Safety segment offers diagnostic test kits, laboratory services, and software used to detect pathogens, toxins, allergens, drug and pesticide residues, and other contaminants in human food and animal feed. The Animal Safety segment supplies veterinary instruments, reagents, immunoassay components, genomics services, and animal care products used in livestock and companion animal markets.

Neogen operates a primarily business-to-business distribution model, selling to food producers and processors, veterinarians, livestock producers, breeding companies, diagnostic laboratories, universities, retailers, and government agencies in the United States and internationally. Products reach end users through direct sales and distributor networks across multiple verticals including milling, meat and poultry, dairy, beverage, and dietary supplements.

Founded in 1981 and headquartered in Lansing, Michigan, Neogen trades on the NASDAQ under the ticker NEOG. It is classified within the Health Care sector under the GICS framework, a categorization that reflects the diagnostic testing orientation of much of its product portfolio.

Headlines to Watch Out For

Food Safety segment grows on pathogen and allergen testing demand
Animal Safety genomics services expand livestock revenue base
3M merger debt servicing pressures margins and capital allocation flexibility

Piotroski VR-10 (Strict) 1.5

Net Income: -7.89m TTM > 0 and > 6% of Revenue
FCF/TA: 0.01 > 0.02 and ΔFCF/TA 2.30 > 1.0
NWC/Revenue: 51.29% < 20% (prev 45.04%; Δ 6.25% < -1%)
CFO/TA 0.02 > 3% & CFO 83.2m > Net Income -7.89m
Net Debt (608.2m) to EBITDA (172.0m): 3.54 < 3
Current Ratio: 3.82 > 1.5 & < 3
Outstanding Shares: last quarter (217.7m) vs 12m ago 0.30% < -2%
Gross Margin: 46.93% > 18% (prev 39.79%; Δ 7.14% > 0.5%)
Asset Turnover: 25.64% > 50% (prev 25.98%; Δ -0.34% > 0%)
Interest Coverage Ratio: 0.85 > 6 (EBIT TTM 50.1m / Interest Expense TTM 59.1m)

Altman Z'' 2.20

A: 0.13 (Total Current Assets 604.6m - Total Current Liabilities 158.2m) / Total Assets 3.35b
B: -0.16 (Retained Earnings -544.3m / Total Assets 3.35b)
C: 0.01 (EBIT TTM 50.1m / Avg Total Assets 3.39b)
D: 1.67 (Book Value of Equity 2.09b / Total Liabilities 1.25b)
Altman-Z'' = 2.20 = BBB

Beneish M -3.21

DSRI: 0.98 (Receivables 146.8m/153.4m, Revenue 870.4m/894.7m)
GMI: 0.85 (GM 39.79% / 46.93%)
AQI: 0.98 (AQ_t 0.67 / AQ_t-1 0.68)
SGI: 0.97 (Revenue 870.4m / 894.7m)
TATA: -0.03 (NI -7.89m - CFO 83.2m) / TA 3.35b)
Beneish M = -3.21 (Cap -4..+1) = AA

What is the price of NEOG shares?

As of August 27, 2026, the stock is trading at USD 11.64 with a total of 978,328 shares traded. Over the past week, the price has changed by +0.61%, over one month by +24.63%, over three months by +27.35% and over the past year by +107.86%.

Current recommended Stop Loss: 11.00 (which is 5.5% or 1.4 ATR below the current price).

Is NEOG a buy, sell or hold?

Neogen has received a consensus analysts rating of 4.33. Therefore, it is recommended to buy NEOG.

StrongBuy: 2
Buy: 0
Hold: 1
Sell: 0
StrongSell: 0

What are the forecasts/targets for the NEOG price?

Analysts Target Price	13	11.7%

Neogen (NEOG) - Fundamental Data Overview as of 22 August 2026

Market Cap USD = 2.58b (2.58b USD * 1.0 USD.USD)
P/E Forward = 16.0
P/S = 2.9637
P/B = 1.2659
P/EG = 0.6575
Revenue TTM = 870.4m USD
EBIT TTM = 50.1m USD
EBITDA TTM = 172.0m USD
Long Term Debt = 793.7m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 793.7m USD (corrected: LT Debt 793.7m + ST Debt none)
Net Debt = 608.2m USD (calculated: Debt 793.7m - CCE 185.5m)
Enterprise Value = 3.19b USD (2.58b + Debt 793.7m - CCE 185.5m)
Interest Coverage Ratio = 0.85 (Ebit TTM 50.1m / Interest Expense TTM 59.1m)
EV/FCF = 99.93x (Enterprise Value 3.19b / FCF TTM 31.9m)
FCF Yield = 1.00% (FCF TTM 31.9m / Enterprise Value 3.19b)
FCF Margin = 3.67% (FCF TTM 31.9m / Revenue TTM 870.4m)
Net Margin = -0.91% (Net Income TTM -7.89m / Revenue TTM 870.4m)
Gross Margin = 46.93% ((Revenue TTM 870.4m - Cost of Revenue TTM 461.9m) / Revenue TTM)
Gross Margin QoQ = 47.85% (prev 46.88%)
Tobins Q-Ratio = 0.95 (Enterprise Value 3.19b / Total Assets 3.35b)
Interest Expense / Debt = 7.44% (Interest Expense 59.1m / Debt 793.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 39.6m (EBIT 50.1m * (1 - 21.00%))
Current Ratio = 3.82 (Total Current Assets 604.6m / Total Current Liabilities 158.2m)
Debt / Equity = 0.38 (Debt 793.7m / totalStockholderEquity, last quarter 2.09b)
Debt / EBITDA = 3.54 (Net Debt 608.2m / EBITDA 172.0m)
Debt / FCF = 19.07 (Net Debt 608.2m / FCF TTM 31.9m)
Total Stockholder Equity = 2.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.23% (Net Income -7.89m / Total Assets 3.35b)
RoE = -0.37% (Net Income TTM -7.89m / Total Stockholder Equity 2.10b)
RoCE = 1.73% (EBIT 50.1m / Capital Employed (Equity 2.10b + L.T.Debt 793.7m))
RoIC = 1.26% (NOPAT 39.6m / Invested Capital 3.14b)
WACC = 10.84% (E(2.58b)/V(3.37b) * Re(12.37%) + D(793.7m)/V(3.37b) * Rd(7.44%) * (1-Tc(0.21)))
Discount Rate = 12.37% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.35 | Cagr: 0.23%
[DCF] Terminal Value 67.22% ; FCFF base≈31.9m ; Y1≈32.0m ; Y5≈33.9m
[DCF] Fair Price = N/A (negative equity: EV 370.6m - Net Debt 608.2m = -237.6m; debt exceeds intrinsic value)
EPS Correlation: -96.64 | EPS CAGR: -20.73% | SUE: 1.39 | # QB: 3
Revenue Correlation: -93.97 | Revenue CAGR: -2.40% | SUE: 2.17 | # QB: 4
EPS current Quarter (2026-08-31): EPS=0.05 | Chg30d=+6.60% | Revisions=-25% | Analysts=3
EPS next Quarter (2026-11-30): EPS=0.09 | Chg30d=-3.52% | Revisions=-25% | Analysts=3
EPS current Year (2027-05-31): EPS=0.31 | Chg30d=+3.33% | Revisions=-25% | GrowthEPS=-3.1% | GrowthRev=+1.5%
EPS next Year (2028-05-31): EPS=0.38 | Chg30d=-9.52% | Revisions=-25% | GrowthEPS=+22.6% | GrowthRev=-2.0%
[Analyst] Revisions Ratio: -57% (up=0, down=4)